Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
pharmaphorum2d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
El País in English11h
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
HIV cases rising in Alberta, sparking need for broad outreach, experts say
Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...
El País in English1d
HIV infection in six transplant patients in Brazil points to nepotism and greed of a laboratory
Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Daily Maverick on MSN2d
Alarming rise in HIV among drug users as government fails to implement policy
Less than half of those who tested positive for HIV in Pretoria were aware of their HIV status. As such they would not have ...
News2415h
Accountability is critical at National Aids Council, says new civil society leader
The South African National Aids Council is meant to play a co-ordinating role in the country’s response to HIV, bringing ...
Medscape5d
Dolutegravir: A New HIV Integrase Inhibitor for the Treatment of HIV Infection
Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...